Multiple Myeloma
📧 Sign up to get email alerts when something new happens for Multiple Myeloma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2025-06-29Clinical Trial Update: UARK 2008-02 A Trial for High-risk Myeloma Evaluating Accelerating and Sustaining Complete Remission [Phase 2]
Phase 2 trial by the University of Arkansas for high-risk multiple myeloma evaluating accelerating and sustaining complete remission is curr…
-
CLINICAL_TRIALS research · 2025-06-29Clinical Trial Update: UARK 2013-13, Total Therapy 4B - Formerly 2008-01 - A Phase III Trial for Low Risk Myeloma [Phase 3]
This is an update on a Phase III trial (Total Therapy 4B) for low-risk multiple myeloma (NCT00734877) led by the University of Arkansas; the…
-
CLINICAL_TRIALS research · 2025-06-29Clinical Trial Update: Multiple Myeloma Molecular Monitoring Study
Horizon Health Network reports that its study on molecular monitoring for multiple myeloma is currently active but not recruiting.
-
CLINICAL_TRIALS trial_result · 2025-06-27Clinical Trial Update: A Study to Compare the Effects of Elranatamab (PF 06863135) Versus Standard of Care (SOC) in Patients With Multiple Myeloma (MM) in Germany and US
A completed study comparing Elranatamab (PF-06863135) to standard-of-care therapy in multiple myeloma patients in Germany and the United Sta…
-
CLINICAL_TRIALS research · 2025-06-27Clinical Trial Update: A Prospective, Non-interventional, Multinational, Observational Study With Isatuximab in Patients With Relapsed and/or Refractory Multiple Myeloma (RRMM)
This document reports on a prospective, non-interventional observational study evaluating isatuximab in patients with relapsed and/or refrac…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2025-06-27Clinical Trial Update: A Clinical Study Comparing SG301 Plus Pomalidomide and Dexamethasone to Placebo Plus Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma Patients [Phase 3]
Phase 3 trial evaluating SG301 in combination with pomalidomide and dexamethasone vs placebo with pomalidomide and dexamethasone in relapsed…
-
CLINICAL_TRIALS research · 2025-06-27Clinical Trial Update: Efficacy of 68Ga-Pentixafor PET/MR in Detecting Non-Hodgkin Lymphoma and Multiple Myeloma Lesions
A clinical trial update describes evaluating 68Ga-Pentixafor PET/MR for detecting lesions in non-Hodgkin lymphoma and multiple myeloma; the …
-
CLINICAL_TRIALS research · 2025-06-27Clinical Trial Update: Gustabor Phase 1 - AI-based Creation of a Nutritional Plan to Compensate for Chemotherapy-induced Taste Disorders [NA]
Phase 1 clinical trial update for Gustabor exploring an AI-driven nutritional plan to compensate for chemotherapy-induced taste disorders in…
-
CLINICAL_TRIALS trial_result · 2025-06-26Clinical Trial Update: Ixazomib and Dexamethasone Versus Ixazomib, Dexamethasone and Lenalidomide, Randomized With NFKB2 Rearrangement [Phase 2]
Phase 2 randomized trial comparing ixazomib and dexamethasone with and without lenalidomide in relapsed/refractory multiple myeloma; results…
-
CLINICAL_TRIALS research · 2025-06-26Clinical Trial Update: Up-front CART-BCMA With or Without huCART19 in High-risk Multiple Myeloma [Phase 1]
A Phase 1 study update evaluating upfront CART-BCMA with or without huCART19 in high-risk multiple myeloma. The trial status is ACTIVE_NOT_R…
-
CLINICAL_TRIALS trial_result · 2025-06-26Clinical Trial Update: CART-38 in Adult AML and MM Patients [Phase 1]
Phase 1 study of CART-38 in adults with acute myeloid leukemia and multiple myeloma has been terminated; this update notes the status of the…
-
CLINICAL_TRIALS research · 2025-06-25Clinical Trial Update: PET/MR Scan With [68Ga]Ga-PentixaFor (CXCR4) vs Standard of Care (SOC) for Initial Staging and Follow up in Multiple Myeloma (MM) [NA]
A recruiting clinical trial evaluating PET/MR imaging with the CXCR4-targeting tracer [68Ga]Ga-PentixaFor versus standard of care for initia…
-
CLINICAL_TRIALS trial_result · 2025-06-25Clinical Trial Update: CART-BCMA Cells for Multiple Myeloma [Phase 1]
Phase 1 trial of CART-BCMA CAR-T cells for multiple myeloma has completed.
-
CLINICAL_TRIALS trial_result · 2025-06-25Clinical Trial Update: Kidney Therapy for Free Light Chain Removal in Patients With Multiple Myeloma & Cast Nephropathy
Clinical trial update indicates completion of a kidney therapy approach to remove free light chains in patients with multiple myeloma and ca…
-
CLINICAL_TRIALS trial_result · 2025-06-24Clinical Trial Update: Dexamethasone, Elotuzumab, and Pomalidomide in Treating Patients With Refractory Multiple Myeloma [Phase 2]
Phase 2 study of dexamethasone, elotuzumab, and pomalidomide in patients with refractory multiple myeloma; the trial has completed and resul…
-
CLINICAL_TRIALS research · 2025-06-24Clinical Trial Update: Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders [Phase 2]
Phase 2 clinical trial evaluating myeloablative allogeneic hematopoietic stem cell transplantation from related or unrelated donors for a br…
-
CLINICAL_TRIALS research · 2025-06-24Clinical Trial Update: The Safety and Efficay Investigation of CAR-T Cell Therapy for Patients With Hematological Malignancies [NA]
A clinical trial is recruiting to evaluate an investigational CAR-T cell therapy for hematologic malignancies, including acute lymphoblastic…
-
CLINICAL_TRIALS research · 2025-06-22Clinical Trial Update: Sequential CAR-T Cells Targeting BCMA/GPRC5D in Patients With Relapsed/ Refractory Multiple Myeloma [Phase 1, Phase 2]
A clinical trial update for a sequential CAR-T cell therapy targeting BCMA and GPRC5D in relapsed/refractory multiple myeloma (Phase 1/2, re…
-
CLINICAL_TRIALS research · 2025-06-19Clinical Trial Update: A Study Designed to Evaluate the Safety and Efficacy of Venetoclax Plus Dexamethasone (VenDex) Compared With Pomalidomide Plus Dexamethasone (PomDex) in Participants With t(11;14)-Positive Relapsed or Refractory Multiple Myeloma. [Phase 3]
This Phase 3 trial compares venetoclax plus dexamethasone versus pomalidomide plus dexamethasone in t(11;14)-positive relapsed or refractory…
-
CLINICAL_TRIALS trial_result · 2025-06-19Clinical Trial Update: Safety, Efficacy, and Pharmacokinetics of Continuous Subcutaneous Lenalidomide in Multiple Myeloma (MM) [Phase 1, Phase 2]
A Phase 1/2 clinical trial is evaluating continuous subcutaneous lenalidomide in patients with multiple myeloma, focusing on safety, efficac…
-
CLINICAL_TRIALS research · 2025-06-19Clinical Trial Update: Long-term Follow-up Registry Study of Equecabtagene Autoleucel Injection
This document reports a long-term follow-up registry study of Equecabtagene Autoleucel for multiple myeloma, currently recruiting.
-
EMA approval · 2025-06-18EMA Authorised: Phelinun (melphalan hydrochloride) — ADIENNE S.r.l. S.U.
The EMA authorised Phelinun (melphalan hydrochloride) for multiple cancers including multiple myeloma, Hodgkin lymphoma, non-Hodgkin lymphom…
-
CLINICAL_TRIALS trial_result · 2025-06-18Clinical Trial Update: Feasibility, Safety and Effectivity of an Exercise Intervention for Newly Diagnosed Multiple Myeloma Patients During Induction Therapy [NA]
A clinical trial update evaluating the feasibility, safety, and effectiveness of an exercise program for newly diagnosed multiple myeloma pa…
-
CLINICAL_TRIALS trial_result · 2025-06-17Clinical Trial Update: A Comparative Clinical Study to Determine the Optimal Initial Therapy for Multiple Myeloma
This document reports the results of a completed comparative clinical trial intended to determine the optimal initial therapy for multiple m…
-
FDA approval · 2025-06-16FDA Approved: PLERIXAFOR — Original Application (Camber Pharmaceuticals, Inc.)
FDA approved a generic version of plerixafor (Mozobil) for mobilizing hematopoietic stem cells in adults with non-Hodgkin lymphoma or multip…